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Abstract:  
Background: The design of anticancer therapies with high anti-tumour efficacy and reduced toxicity continues to 
be challenging. Anti-cancer prodrug and antibody-drug-conjugate (ADC) strategies that can specifically and 
efficiently deliver cytotoxic compounds to cancer cells have been used to overcome some of the challenges. Key 
to the success for many of these strategies is a self-immolative linker, which after activation can release the drug 
payload. Various types of triggerable self-immolative linkers are used in prodrugs and ADCs to improve their 
efficacy and safety. 
 
Objective: Numerous patents have reported the significance of self-immolative linkers in prodrugs and ADCs in 
cancer treatment. Based on the recent patent literature, we summarise methods for designing the site-specific 
activation of non-toxic prodrugs and ADCs in order to improve selectivity for killing cancer cells.  
 
Methods: In this review, an integrated view of the potential use of prodrugs and ADCs in cancer treatment are 
provided. This review presents recent patents and related publications over the past ten years to 2020. 
 
Results: The recent patent literature has been summarised for a wide variety of self-immolative PABC linkers 
which are cleaved by factors including responding to the difference between the extracellular and intracellular 
environments (pH, ROS, glutathione), by over-expressed enzymes (cathepsin, plasmin, β-glucuronidase) or 
bioorthogonal activation. The mechanism for self-immolation involves the linker undergoing a 1,4- or 1,6-
elimination (via electron cascade) or intramolecular cyclisation to release cytotoxic drug at the targeted site. 
 
Conclusion: This review provides the commonly used strategies from recent patent literature in the development 
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Cancer is an extensive group of diseases and the second leading cause of death globally after 
cardiovascular disease [1]. There are more than 100 different types of cancers categorized based on the type of 
cells or organs from which they originate. In 2018, the most frequently diagnosed cancers worldwide were lung 
(11.6%), breast (11.6%), colorectal (10.2%), prostate (7.1%), stomach (8.2%) and liver (8.2%) [2].  
In order to comprehend mechanisms of the disease in its diverse manifestations, Hanahan and Weinberg 
proposed the ‘hallmarks of cancer’. They put forward eight hallmarks of cancer along with two emerging 
characteristics namely; sustaining proliferative signalling, evading growth suppressors, avoiding immune 
destruction, enabling replicative immortality, activating invasion and metastasis, inducing angiogenesis, resisting 
cell death, deregulating cellular energetics, in addition to tumour-promoting inflammation, as well as genome 
instability and mutation [3]. 
1.2 Causes of Cancer 
 There is no one single cause of cancer. The factors involved may be due to a genetic disorders, lifestyle- 
related factors such as tobacco smoke, diet, alcohol, UV radiation, environmental pollutants, infections, stress, 
obesity or physical inactivity [4].  
1.3 Cancer treatments  
Treatment depends upon the location and specific type of tumour, the stage of the disease as well as 
individual factors of the patient such as age and possible side effects. Surgery remains a mainstay in the cure and 
control of most solid tumours [5]. Marie Curie’s work has contributed significantly to the discovery and 
development of radiation treatment [6]. The conception of immunotherapy in medicine integrates the use of 
constituents of the immune system, including antibodies, cytokines and dendritic cells [7]. Photodynamic therapy 
involves the administration of photosensitizers, which utilize exogenously synthesised reactive oxygen species 
(ROS) to kill cancer cells [8]. Gene therapy aims to alleviate the disease by introducing genetically modified 
materials (e.g. DNA, RNA) [9]. A new and significant turn to the treatment of tumours took place in the 20th 
century in the form of chemotherapy, with the use of nitrogen mustards and folic acid based drugs [10]. Combined 
chemotherapy is a treatment strategy where more than one chemotherapy medication is used.  
Despite the greater efficacy and better survival offered by chemotherapy, patients still face challenges 
associated with poor tumour selectivity, insufficient localised drug concentration, and high toxicity towards 
normal cells/tissue; including the lymphatic system, gut mucosa and bone marrow cells. Numerous drug delivery 
approaches have been developed to augment the efficacy e.g. nanoparticles, and reduce toxicity of existing anti-
cancer agents. One promising area for improving tumour selectivity is prodrug therapy. 
1.4 Prodrugs 
In 1958, Adrien Albert introduced the term “prodrug” [11] meaning any compound that undergoes 
biotransformation before showing its pharmacological effects. Prodrugs have been reviewed in detail by others 
[12, 13], including a brief description of the types of prodrugs and their use in anti-cancer therapy. Over the last 
few years, there has been a growing development in the physicochemical, biopharmaceutical and/or 
pharmacokinetic properties of pharmacologically active compound by the application of prodrug strategies [14]. 
During the period 2008-2017, approximately 30 prodrugs were approved by the US Food and Drug Administration 
(FDA), which accounts for more than 12% of all small molecule new chemical entities [13]. 
1.5 Antibody drug conjugates  
Drug discovery has generally focused on small-molecule anti-cancer chemotherapeutic drugs, but these 
can cause significant side effects such as toxicity, drug resistance and lack of selectivity against cancer cells. 
Antibody drug conjugates (ADCs) are an emergent class of therapies for targeted drug delivery treatment, and 
consist of monoclonal antibodies (mAbs) attached to biologically active cytotoxic agents through chemical linkers 
[15]. At the time of collating this review, there have been nine ADCs approved by the FDA namely trastuzumab 
deruxtecan (Enhertu®) [16], gemtuzumab ozogamicin (Mylotarg®), brentuximab vedotin (Adcetris®), 
trastuzumab emtansine (Kadcyla®), inotuzumab ozogamicin (Besponsa®) [17], polatuzumab vedotin-piiq 
(Polivy®) [18],  enfortumab vedotin (Padcev®) [19], sacituzumab govitecan (Trodelvy®) [20] and belantamab 
mafodotin (Blenrep®) [21]. 
1.6 Linker design 
The linker system plays a significant role in both prodrug and ADC design, where the linker connects 
the cytotoxic drug to the antibody or an activatable moiety [22-25]. The linker must be stable in the blood stream 
to avoid release of the cytotoxic drug prior to reaching the target site. Upon reaching the target cells, the linker 
must possess the property of releasing the drug in its active form via a specific trigger or during lysosomal 
degradation of the ADCs. The drug-to-antibody ratio, the number of drug molecules attached per antibody via a 
linker, plays an important role in stability and homogeneity of ADCs [26].  
1.7 Self-immolative linkers  
The para-aminobenzyloxycarbonyl (PABC) type self-immolative linker was introduced in 1981 by 
Katzellenbogan to resolve problems in prodrug design [27]. Since the first report, this and other self-immolative 
linkers have found widespread applications in the fields of prodrugs [28], antibody drug conjugates [29], drug 
delivery systems [30], imaging probes [31], sensors for chemicals or enzymes [32, 33], and materials science [34]. 
Self-immolative prodrugs consist of three components, a biologically active molecule (drug), the self-immolative 
linker, and a reactive trigger group that responds to a specific stimulus (e.g. nitro, amide, azide). Upon application 
of the specific stimulus, the covalent bond between the trigger and the self-immolative linker undergoes a cascade 
of disassembly reactions ultimately leading to release of the active molecule [35, 36]. From a mechanistic point 
of view, after the stimulus activates the trigger group, drug or payload release is thermodynamically driven and 
takes place via either an electron cascade for PABC-type linkers (1,4-, 1,6-, or 1,8-elimination) or an 




Figure 1 Common types of self-immolative/elimination linkers that release payload (drug) following a 
PABC-type electron cascade mechanism (A-C) and a cyclisation-mediated mechanism (D-E). X = Electron-
donating (A-C) or nucleophilic (E) substituent. 
 
Drug triggering and subsequent self-immolative release, can be carried out by a number of methods 
including;  
1. enzymatic cleavage utilising enzymes over-expressed in tumours, such as cathepsins and 
plasmin (which produce a newly formed amine) as well as β-glucuronidase [28],  
2. enzymatic reduction of nitro substituents [38], 
3. reduction of disulphide bonds by the action of glutathione or another thiol reducing agents [39],  
4. oxidation of aryl boronic acid/esters [40], and  
5. bioorthogonal activation strategies such as the tetrazine/trans-cyclooctene and azide/trans-
cyclooctene reactions [41].  
 
2. Patents on self-immolative linkers in cancer prodrugs 
 As highlighted above, self-immolative linkers have proven very useful across a number of fields, but the 
most significant use has been in the design of stimuli-responsive prodrug and ADC activation [42, 43]. 
 Kratz, Warnecke and others (KTB Tumorforschungsgesellschaft mbH, Germany) have produced 
numerous patents covering different self-immolative cancer prodrugs. Kratz et al initially reported prodrugs 
comprising a dendritic polyglycerol core with a polyethylene glycol (PG) shell attached to the cytotoxic agents 
through a linker (Fig. 2). Cathepsin B releases the drug-PABC conjugate via amide cleavage, and a 1,6-self -
immolation of the PABC linker leads to release of free drug (e.g. Doxorubicin). Cytotoxicity studies using the 
prodrug were carried out on triple-negative breast cancer cells MDA-MB231 and pancreatic tumour cells AsPC1 
LN and produced IC50 values of 0.50 and 1.80 µM respectively for a 10 kDa dendrimer compared with the 
doxorubicin control giving IC50 values of 0.14 and 0.36 µM respectively [44]. 
 
 
Figure 2: Prodrug containing thiolated polyglycerolamine (PG) linked to the 6-maleimidopropyl-Phe-Lys-PABC-
Doxorubicin [44]. 
 
Kratz et al (KTB Tumorforschungsgesellschaft mbH, Germany) also synthesised a prodrug cleavable by 
prostate-specific antigen (PSA, a serine protease) (Fig. 3). PSA-mediated cleavage initiates a 1,6-elimination via 
the PABC linker. An albumin-bound form of the prodrugs showed the albumin-conjugates were hydrolysed  
efficiently within 3 hours releasing the free drug in LNCaP prostate tumour tissue homogenates [45, 46]. 
 
 
Figure 3: A general formula for prodrugs comprising a protein binding moiety (R, e.g. maleimide), a peptide 
sequence, a p-aminobenzyloxycarbonyl (PABC) self-immolative linker and cytotoxic agent [45, 46]. Cytotoxic 
drugs used included doxorubicin and paclitaxel. The mechanism of 1,6-elimination via the p-
aminobenzyloxycarbonyl linker which releases carbon dioxide along with the cytotoxic drug is shown above (in 
Figure 2). 
 
Kratz et al (KTB Tumorforschungsgesellschaft mbH, Germany) went on to design a range of the 
bisphosphonate prodrugs incorporating a cathepsin B cleavable peptide with a PABC linker or an acid sensitive 
hydrazone bond used for the treatment of bone related cancer. Binding studies were performed on these prodrugs  
(Fig. 4) at pH 7.4 and the percentage bound to native bone was found to be 50-80% after several hours [47, 48]. 
Part of the work was published [49]. 
 
 
Figure 4: Bisphosphonate prodrugs were cleaved under acidic conditions (top – no self-immolation) or by 
cathepsin B with PABC 1,6-elimination to release the anti-cancer drug doxorubicin [47, 48]. 
 
Warnecke and Müller (also of KTB Tumorforschungsgesellschaft mbH, Germany) developed 
compounds with an imine as an acid-labile trigger group attached through double PABC linkers to a drug, where 
the imine bond is cleaved at acidic pH (Fig. 5). Half-lives of imine hydrolysis were determined by measuring the 
decrease of the concentration of the imine and the increase of the concentration of the hydrolysis products by 
fluorescence methods, HPLC, infrared spectroscopy and NMR spectroscopy with compounds showing  minimum 




Figure 5: Aryl imine prodrugs that release the cytotoxic drugs (e.g. 5-fluorouracil and 6-mercaptopurine) at pH 
5 [50]. The mechanism of elimination following acid-hydrolysis involves an initial 1,6-elimination revealing a 
second free aniline primed for an additional 1,6-elimination. In the case of 5-fluorouracil, an additional self-
immolation would be required to release the parent drug (shown in box). 
 
 Leamon et al (Endocyte, USA, founded in the Purdue Research Park, acquired by Novartis), prepared a 
range of anti-folate conjugates that bind to the folate receptor (Fig. 6). A series of folate analogues were evaluated 
using a folate receptor positive KB (cervical carcinoma (HeLa derivative)) cell assay for their ability to compete 
with folate and the relative binding affinity was determined at 37°C with vinblastine and mitomycin C derivatives 
showing relative affinities of 0.47 and 0.59 respectively [51]. 
 
 
Figure 6: Anti-folate conjugates cleaved by an exogenous or endogenous nucleophile (glutathione or a 
bioreducing agent) releasing the anti-cancer drug (e.g. vinblastine) via a cyclisation-mediated elimination step. 
Other drugs reported by the inventors include mitomycin C [51].  
   
Cohen et al (The Regents of the University of California, USA) reported prodrugs that include an anti-
cancer moiety covalently linked to an oxidation sensitive self-immolative linker (Figure 7A) [52]. The prodrugs 
include a method of inhibiting the metalloprotein MMP -12 which has been found to be overexpressed in several 
different tumour types including non-small cell lung cancer, skin cancer, ovarian cancer , and pancreatic cancer 
[53]. The metal binding moiety (e.g. 1-hydroxypyridin-2(1H)-one; 1,2-HOPO-2) is formed from the reaction of 
the oxidation-sensitive prodrug and a ROS, e.g. H2O2 (Fig. 7B). The boronic ester is oxidised to the phenol 
followed by 1,6-elimination/immolation (Fig. 7B). IC50 values of 17.8 and 12.9 µM for “proinhibitors” and 0.053 
and 0.035 µM for inhibitors 1,2-HOPO-2 and PY-2 respectively were reported based on a fluorescence assay 
against MMP-12 [52, 54]. Compounds 1,2-HOPO and PY-2 were originally developed for ischemia–reperfusion 
injury (following stroke), the approach first described by Cohen et al. [54]. There has since been significant efforts 
to develop the arylboronic ester self-immolative prodrugs for cancer [55].  
 
 
Figure 7: A) Arylboronic ester prodrugs of 1,2-HOPO-2 and PY-2 designed for reaction with reactive oxygen 
species (ROS) [52]. B) Activation of the prodrug with H2O2 (ROS), releasing the matrix metalloprotease inhibitor 
hydroxypyridinone (1,2-HOPO-2). 
 
 Bierbach and Ding (Wake Forest University, USA) reported dual action acridine cisplatin compounds 
that have shown superior efficacy over standard cisplatin compounds (Fig. 8). These compounds have shown 
enhanced cytotoxicity in several different types of cancers including NCI-H460 non-small cell lung cancer 
(NSCLC) cells, leukaemia, and effective tumour growth inhibition in H460 xenograft models. The compounds 
showed promising cytotoxic activity in a cell viability assay (IC50= 0.026 – 0.35 µM against NCI-H460 cells) 
[56]. Parts of this work have also been published [57]. 
 
 
Figure 8: pH-Sensitive release of acridine cisplatin compounds where R is a targeting moiety e.g. kinase inhibitor 
[56]. 
 
 Robillard et al (Tagworks Pharmaceuticals B.V., Netherlands) designed a drug release mechanism via 
bioorthogonal activation using an inverse-electron-demand Diels-Alder (IEDDA) reaction. The prodrug contains 
a dienophile (trans-cyclooctene) that masks the drug (doxorubicin). The drug is released upon activation by a 
diene (tetrazine) via a 1,4-elimination (Fig. 9) [58, 59]. The trigger and the activator undergo a fast, bioorthogonal 
reaction resulting in the release of the drug within 4 h. The release of drug from axial trans-cyclooctene–
doxorubicin [60] was measured using LCMS with results showing up to 75% release in serum [59].  
 
Figure 9: Tetrazine-induced release of doxorubicin from trans-cyclooctene-doxorubicin prodrug [58, 60]. 
 
 Papot et al (Centre Nationale de Recherche Scientifique and Universite de Poitiers, France) prepared a 
self-immolative linker based on PABC that is useful for the preparation of novel anti-cancer prodrugs, including 
dendrimers, capable of targeting tumour cells in vivo via folate receptors (Fig. 10). The cytotoxic agent, e.g. 
doxorubicin, was attached at the benzylic hydroxyl group via a carbamate bond along with a folate moiety joined 
via a PEG linker. Cleavage of a terminal carbohydrate by β-glucuronidase produced the active phenol which 
undergoes 1,6-elimination. The cytotoxicity of dendritic (2 molecules doxorubicin to one folate) prodrugs  was 
close to that of doxorubicin (range of 0.1 < IC50 < 0.15 µM against LAM type KG1 leukemia cells) [61].  
 
Figure 10: A general formula (box) for the doxorubicin prodrug with a self-immolative linker. Targeted anti-
cancer prodrug shown with doxorubicin and folate targeting moiety. Activation was via β-glucuronidase cleavage 
of the terminal carbohydrate [61]. 
 
 Prijovic et al (Academia Sinica, Taipei, Taiwan) reported a second-generation camptothecin glucuronide 
prodrug (BQC-G) that showed better aqueous solubility than a camptothecin derivative of 5,6-dihydro-4H-
benzo(de)quinolone-camptothecin (BQC) (Fig. 11). Cytotoxicity results were good (low nM range) against a 
number of cell lines in the absence of human serum albumin and were improved when activated with β-
glucuronidase [IC50 = 1.33 nM (CLI-5 human lung cancer cells); IC50 = 1.35 nM (LS174T colon cancer cells); 
IC50 = 1.44 nM (CaSki cervical carcinoma cells); IC50 = 2.0 nM (EJ human bladder cancer cells)]. BQC-G when 
activated with β-glucuronidase followed by 1,6-elimination exhibited a remarkable cytotoxicity (IC50 =13.3 nM 
against CL1-5 cells) whereas in the presence of human serum albumin without β-glucuronidase showed lower 
cytotoxicity (IC50 =1080 nM) [62, 63].  
 
Figure 11: BQC-G, a potent (IC50 = 13.3 nM) tumour selective anti-cancer prodrug [62, 63]. 
 
 Beria et al (Nerviano Medical Sciences S.R.L., Nerviano, Italy) have developed new functionalized 
thieno-indole derivatives based around duocarmycins (minor groove binding alkylating agents) that are potent 
against cellular proliferation disorders (Fig. 12). Their patent covers self-immolative groups including the PABC 
linker. In vitro cell proliferation assays were performed on the human ovarian cancer cell line A2780 and breast 
cancer cell line MCG7 with all compounds showing IC50 < 0.5 µM [64].  
 
 
Figure 12: Example structure of the functionalized thieno-indole derivatives with an enzyme activated PABC self-
immolative linker [64]. 
 
 Kim et al (Pharosgen Co, Ltd, Seoul, Korea) designed a series of prodrug conjugates that induce and 
amplify apoptosis. Upon activation of the prodrug by caspase and 1,6-elimination via a PABC linker, the cytotoxic 
drug (e.g. doxorubicin) was released. Cleavage studies were performed using recombinant human caspase-3 and 
monitored by HPLC (Table 1) [65]. A human serum albumin conjugate (Maleimide-KGDEVD-PABC-
Doxorubicin) showed no noticeable cytotoxic effects up to 100 µM. However, when activated with caspase-3, it 
showed a similar degree of cytotoxicity to free doxorubicin against mouse squamous cell carcinoma SCC7 cells 
and MDA-MB-231 triple negative breast cancer cells.  
 
Table 1: Chemotherapeutic prodrug conjugates comprising the caspase cleavable peptides, attached to cytotoxic 




1    Maleimide-KGDEVD-PABC-Doxorubicin 
2     Maleimide-KGDEVD-PABC-Daunorubicin 
3     Maleimide-KGDEVD-PABC-Paclitaxel 
4     Maleimide-KGDEVD-PABC-MMAE 
5           Maleimide-DEVD-PABC-Doxorubicin 
6            Maleimide-DIED-PABC-Doxorubicin 
7            Maleimide-DLVD-PABC-Doxorubicin 
10  Pyridyldithiol-KGDEVD-PABC-Doxorubicin 
11             Oleate-KGDEVD-PABC-Doxorubicin 
12            Glycol-KGDEVD-PABC-Doxorubicin 
13    Hyaluronan-KGDEVD-PABC-Doxorubicin 
14             Folate-KGDEVD-PABC-Doxorubicin 
15                        RGDEVD-PABC-Doxorubicin 
16              CQRPPRDEVD-PABC-Doxorubicin 
17                        RGDEVD-MBA-Doxorubicin 
PABC – p-aminobenzyloxycarbonyl; MMAE – monomethyl auristatin E; MBA – Maleimidobutyric acid 
 
 
3. Patents on self-immolative linkers in antibody drug conjugates 
Antibody-drug conjugates have proven to be an effective method of selectively delivering a small 
cytotoxic payload to a targeted cell [22-24]. The incorporation of self-immolative linkers connected to the ADCs 
have proven to be an effective method to selectively deliver cytotoxic agents to these targeted cells. 
 Feng (Seattle Genetics, Inc., Bothell, WA, USA) reported on ADCs incorporating a cathepsin B peptide 
substrate along with heterocyclic self-immolative linkers fused to anti-cancer drugs containing amine, hydroxyl, 
sulfhydryl or carboxyl functional groups (Fig. 13) [66]. The heterocyclic linkers were designed to improve 
properties of drug-ligand conjugates by optimising the structure of the linker to overcome possible poor solubility, 
aggregation and optimise enzymatic substrate recognition. The detailed activity data was not available in the 
published patent.  
 
 
Figure 13: ADC conjugate exposed to cathepsin B, resulting in cleavage at the position shown and release of the 
amine-containing drug (e.g. mitomycin C, doxorubicin) after 1,6-self-immolation from the amino-thiazole [66]. 
 
 Beria et al (Genentech, Inc., South San Francisco, CA USA) reported the synthesis of numerous ADCs 
(e.g. Fig. 14) that consist of the antibody linked to a cathepsin B substrate, a PABC linker and the anti-cancer 
drug. The average drug/antibody ratio (DAR) of the synthesised compounds was found to be 1.25  3.4 [67]. 
Many compounds showed IC50 < 0.1 µg/ml against the human breast cancer cell lines SK-BR-3, BT-474, MCF7 
and doxorubicin-resistant Her2. The doxorubicin ADC in (Fig. 14) is first hydrolysed by cathepsin B, followed 
by two self-immolative events; a 1,6-self-immolation of the PABC group and then an intramolecular cyclisation 
to release the drug.  
 
 
Figure 14: ADC attached through N-hydroxysuccinimide-ketal, maleimide-ketal, a PABC linker and nemorubicin 
[67]. 
 
 Boyd et al (Medarex, Inc., USA) designed ADCs where the drug and the antibody were linked via a 
peptidyl hydrazone linker that following acid-catalysed hydrolysis of the hydrazone, led to a cyclisation mediated 
self-immolation of the active drug (Fig. 15). The proliferation assay was performed on promyelocytic leukemia 




Figure 15: (A) Duocarmycin ADC examples with hydrazine linkers that undergo cyclisation mediated self-
immolation via 5- or 6-membered rings [68]. ADC 1 (top) is designed to undergo a double cyclisation mediated 
self-immolation releasing two 5-membered rings while ADC 2 is designed to undergo a single self-immolative 
cyclisation to release a 6-membered ring. (B) An example self-immolative event for ADC 2 that releases the 
active drug and a 6-membered ring as by-product (mechanism shown following hydrolysis of hydrazone).  
 
 Dushin et al (Pfizer Inc., USA) submitted a patent application describing the synthesis of ADCs with an 
enhanced pharmacokinetic profile for the treatment of cancer. The antibody anti-5T4 was linked via the non-
natural amino acid p-acetyl-L-phenylalanine along with a protease cleavage sequence to the drug dolastatin via 
the self-immolative PABC linker (Fig. 16). A cytotoxicity assay of compounds was performed on 5T4 expressing 
cell lines with an IC50 range of 16 – 56 (Ab ng/mL) against MDA-MB-435/5T4 breast cancer cells expressing a 
high level of the 5T4 antigen [69]. Part of the work was published [70]. 
  
Figure 16: An ADC consisting of a cleavable peptide linker, and the self-immolative PABC linker attached to 
anti-cancer drug dolastatin via the non-natural amino acid p-acetyl-L-phenylalanine [69]. 
 
 Lin et al (BioAlliance C.V., Netherlands, and Abgenomics International Inc, USA) designed ADCs in 
which a hydrophilic self-immolative linker (PABC) which undergoes 1,6-elimination, was attached to a cleavable 
peptide linker and an anti-cancer drug; e.g. dolastatin or derivatives of duocarmycins (Fig. 17). In vitro 
cytotoxicity activity of the antibodies c5D7 and h5F1Ca.1 functionalised with the compounds were tested in DLD-
1 and COLO 205 human colorectal cancer cells, human gastric cancer SNU-16 cells, Panc02.03B pancreatic 
cancer cells and the % inhibition were found to be 62% (0.3 µg/mL; DLD-1) – 98% (3 µg/mL; SNU-16) [71, 72]. 
 
Figure 17: An example ADC consisting of a peptide linker attached to the cytotoxic drug dolastatin via a self-
immolative PABC linker [71, 72]. Initial activation, revealing the self-immolative PABC linker, is promoted by 
endogenous enzyme hydrolysis by cathepsins B or D.  
 
 Morrison et al (Agensys, Inc. and Seattle Genetics, Inc., USA) synthesised ADCs consisting of the 
antibody 158P1D7 attached to a cleavable peptide linker incorporating a 1,6-self-immolative PABC linker and an 
anti-cancer drug, e.g. auristatin (Fig. 18). In vitro cytotoxicity of the compound was evaluated on the 
neuroblastoma CHP-212 cell line with an IC50 of 0.91 nM [73]. 
 
 
Figure 18: ADC conjugate reported by Morrison et al. that releases the drug MMAE (monomethyl auristatin E) 
upon endogenous peptide cleavage and subsequent 1,6-self-immolation [73].  
 
 Lyon et al (Seattle Genetics, Inc., USA) developed ADCs that can be triggered via β-glucuronidase 
cleavage releasing active drug following the 1,6-self-immolation of a PABC moiety (Fig. 19). They found that 
the positioning of a PEG unit (designed to mask the hydrophobicity of the drug) parallel to the drug improves the 
pharmacokinetic properties of the conjugates (Fig. 19B) [74]. In vitro cytotoxicity assays were carried out with 
CD30+ Lymphoma cell lines (Karpas299, L540cy and L428) resulting in IC50 values of 0.3 – 0.4 ng/mL 




Figure 19: ADC conjugates reported by Lyon et al [74]. MMAE conjugated to the antibody and linker is released 
upon internalization into the cells, whereby glucuronidase hydrolysis of the carbohydrate unit exposes the PABC-
type linker. Note that in this ADC, a slight variation on the PABC linker was used whereby the hydrolysis of the 
glucuronide revealed a phenolic/hydroxyl group instead of an aniline/amine group. 
 
 Jeffrey et al (Seattle Genetics, Inc, USA) produced ADCs consisting of a cAC10 antibody linked to a 
drug via a β-glucuronide terminated linker containing the 1,6-self-immolating group that is triggered via β-
glucuronidase (Fig. 20). In vitro cytotoxicity assays for the ADCs targeting the CD70 antigen resulted in IC50s of 
0.08  2.7 nM on renal cell carcinoma lines Caki-1 and 786-O (CD70+, CD30-), and IC50s of 0.05  1.2 nM on 
targeting the CD30 antigen with the lymphoma Karpas 299 (CD30+, CD70-) cell line with the active drugs 
auristatin E, F and doxorubicin. The β-glucuronide-based ADCs displayed improved serum stability compared to 




Figure 20: Targeted delivery of anti-cancer drug (e.g. doxorubicin) was achieved upon activation of the ADCs 
by β-glucuronidase triggered self-immolation [76, 78]. 
 
 An et al (Newbio Therapeutics, Inc., China) reported ADCs comprising an antibody attached to a 
tridentate linker (trisubstituted phenyl ring), further conjugated to a peptide-PABC-drug conjugate (e.g. auristatin) 
(Fig. 21). The antigen Her2 binding showed strong affinity with different ADC-drug combinations EC50 23.3  
95.5 ng/mL compared with Herceptin alone (EC50 = 32.5 ng/mL). The potency of the ADC-drug combinations 
was measured by cell proliferation inhibition assay on SK-BR-3 human breast cancer cell line (IC50 = 6.7 – 15.2 
ng/mL). One ADC had an IC50 outside of this range at a higher concentration of 81.1 ng/mL but this lacked the 
peptide-PABC linker [79, 80]. 
 
Figure 21: Attachment of the tridentate linker (left-hand side aromatic ring) to the antibody and the drug with a 
PABC-based self-immolative linker [79, 80].  
 
 Han et al (Newbio Therapeutics, Inc., China) synthesised a series of trimaleimide-linked ADCs of 
different sizes to study the effects on their pharmacokinetic and toxicity properties as well as their potency (Fig. 
22). The trimaleimide linker was attached to a valine-citrulline enzyme cleavage site, followed by a PABC self-
immolating linker designed to release various cytotoxic agents e.g. MMAE (monomethyl auristatin E). The 
synthesised ADCs exhibited drug/antibody ratio (DAR) in the range of 2  4. A cell proliferation assay using SK-
BR-3 breast cancer cell lines resulted in IC50 values in the range of 5.7 – 11.0 ng/mL [81, 82]. 
 
 
Figure 22: Generic template of ADCs comprising the trimaleimide linker with variation in both maleimide linker 
length (n) and extension arm (X; different functional groups and chain length), valine – citrulline – PABC linker 
and the cytotoxic drug e.g. MMAE [81, 82]. 
 
 Steinkuhler et al (Exiris S. R. L., Roma, Italy) reported ADCs comprising an antibody attached to peptide 
linkers and the drug cryptophycin (Fig. 23). The conjugates were activated proteolytically releasing 
diketopiperazine and the cryptophycin derivative. Cryptophycin-52 passed phase I clinical studies but failed phase 
II studies as it lacked efficacy in vivo, had high neurotoxicity, and dose-limiting toxicity at the selected doses. 
However when incorporated into an ADC, the cytotoxicity of the cryptophycin-55 derivative against small cell 
lung cancer cell lines H69 and H69Ar (adriamycin resistant) was improved with IC50 values as low as 0.09 nM 
(against H69) and 0.15 nM (against H69Ar) [83, 84]. Release of active drug from the ADC occurs via self-
immolative cyclisation of a diglycine linker (forming diketopiperazine) or a 1,6-self-immolation via the PABC 
unit. 
 
Figure 23: Upon proteolytic activation the ADCs releases the anti-cancer drug candidate cryptophycin via (A) 
cyclisation-mediated self-immolation or (B) 1,6-self-immolation [83, 84].  
 
 Miao et al (Sorrento Therapeutics, Inc., San Diego, CA, USA) developed ADCs (Fig. 24) that differed 
from those above in their use of pyridine and tetrazole heterocycles as a connector to the antibody. Several 
examples included the PABC linker. Compounds were tested against a range of cell types and were most active 
against the SBKR3 Her2+++ human breast cancer cell line with EC50 values of 0.022 and 0.031 nM (Fig. 24A and 
24B respectively) [85].  
 
Figure 24: ADCs incorporating nitrogen heterocyclic connectors with PABC as the eliminating moiety releasing 
a Nemorubicin derivative [85]. 
 
 
 Van Berkel et al (ADC Therapeutics S.A., China and Medimmune Limited, Cambridge Great Britain) 
reported ADCs with pyrrolobendiazepines (PBDs) and the antibody CD25. In these conjugates the drug was linked 
to the antibody via a peptide linker and a self-immolative group e.g. PABC (Fig. 25). In vitro cytotoxicity of the 
compounds was examined with lymphoma cell lines SU-DHL-1, DAUDI and Karpas299 with EC50 values in the 
range of 0.0002 – 0.001, 0.11 – 0.27 and 0.0007 – 0.003 µg/mL, respectively. The DAR of the ADCs was found 
to be in the range of 1.25 – 2.19 [86].  
 
Figure 25: Activation of the ADCs was performed by cathepsin to release the anti-cancer PBDs [86].  
 
 Dragovich et al (Genentech, Inc, CA, USA) developed pyrrolobenzodiazepine (PBD)-based ADCs 
whereby a peptide linker between the antibody and the drug (monomer or dimer) was incorporated with a 
disulphide or PABC linker. The disulphide ADCs were activated by glutathione reduction, while the PABC ADCs 
were activated proteolytically followed by a 1,6-self-immolation to release active drug (Fig. 26). The cytotoxicity 
of the synthesised compounds was evaluated against KPL-4 (best IC50 = 5.0 ng/mL), SK-BR-3 (best IC50 = 7.0 
ng/mL), WSU-DLCL 2 (best IC50 = 8.56 nM) tumour cells and resulted in EC50s of 1.70 nM or lower [87, 88]. 
Part of the work was published and showed improved activity [89, 90]. 
 
 
Figure 26: Anti-cancer PBD dimers are initially released via proteolytic hydrolysis releasing the boronic ester 
and disulphide prodrug derivatives, which are activated by glutathione and reactive oxygen species [87, 88]. 
 
 Robillard et al (Tagworks Pharmaceuticals B.V., Netherlands) have produced a number of patents on 
ADCs that are activated by the IEDDA reaction (see also Fig. 9 for prodrug example) [91-93]. For example, they 
have produced ADCs consisting of the TAG72 diabody (CC49) attached to a linker comprising a trans-
cyclooctene (TCO) and the drug e.g. MMAE or doxorubicin (Fig. 27 shows MMAE ADC). Activation of the TCO 
leads to release of drug via a 1,4-eliminaton [94], and more recently examples of drug attached to the tetrazine 
followed by addition of TCO as the activator have been reported [60]. The group have also demonstrated 
activation with a tetrazine in which the TCO was released from the ADC via a 1,4-elimination followed by a 
second 1,6-self-immolation to release the cytotoxic drug (Fig. 27) [91]. The cell proliferation assay was performed 
on a doxorubicin prodrug and tetrazine using carcinoma cells A431, with IC50 values of 0.137 – 0.278 µM [91]. 
In a later publication, a CC49-MMAE ADC was activated in vitro and in vivo, providing potent pM cytotoxicity 
[94]. 
 
Figure 27: MMAE ADC conjugate and activation method reported by Robillard et al [91]. Upon activation with 
a tetrazine, TCO triggers the release of anticancer drug auristatin E.  
 
 Agatsuma et al (Daiichi Sankyo Company, Limited, Tokyo, Japan and Sapporo Medical University, 
Sapporo-Shi, Hokkaido, Japan) reported ADCs incorporating antibodies (hRS7 and hTINA1) covalently attached 
to a peptide linker and the drug (Fig. 28). They contain cleavable peptide spacer which triggers a cyclisation to 
release the cytotoxic agent e.g. exatecan. The ADCs exhibited a cell growth inhibitory effect value of GI50 <1 nM 
on TROP2 antigen-positive cell lines BxPC3, NCI-H292, NIH:OVCAR-3, CFPAC-1, FaDu, Calu-3 and CaOV3. 
On the other hand no cell growth inhibitory effect >100 nM was observed on the TROP2 antigen-negative cell 
lines Calu-6 and A375 respectively [95]. 
 
Figure 28: ADCs that are covalently attached to the peptide linker masking the self-immolating group and anti-
cancer drug exatecan [95].  
  
4. Conclusion 
 Self-immolative linkers in prodrugs and antibody drug conjugates have been intensively studied and it is 
well established that these show great potential for cancer treatment. The PABC linkers have huge potential for 
anti-cancer therapy. They have exhibited greater systemic stability over other cleavable linkers and are favoured 
among the prodrugs and ADCs that are currently in clinical trials [96]. Of the nine FDA approved ADCs, three of 
them (brentuximab vedotin, polatuzumab vedotin, enfortumab vedotin) contain the PABC linker [97]. Our review 
attempts to describe the application of linkers in prodrugs as well as antibody drug conjugates that are 
cleaved/activated in the cancer cells specifically by cathepsins, ROS, glutathione, β-glucuronidase, prostate 
specific antigen, caspases and acid catalysed hydrolysis to release cytotoxic drugs at the targeted cell. Although 
extraordinary progress has been achieved in the design and development of these prodrugs, some of the problems 
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